WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.
Osteoporos Int. 2011 Feb;22(2):453-61. doi: 10.1007/s00198-010-1218-1. Epub 2010 Mar 30.
A country-specific FRAX® model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement thresholds.
The objective of this study was to evaluate a Belgian version of the WHO fracture risk assessment (FRAX®) tool to compute 10-year probabilities of osteoporotic fracture in men and women. A particular aim was to determine fracture probabilities that corresponded to the reimbursement policy for the management of osteoporosis in Belgium and the clinical scenarios that gave equivalent fracture probabilities.
Fracture probabilities were computed from published data on the fracture and death hazards in Belgium. Probabilities took account of age, sex, the presence of clinical risk factors and femoral neck bone mineral density (BMD). Fracture probabilities were determined that were equivalent to intervention (reimbursement) thresholds currently used in Belgium.
Fracture probability increased with age, lower BMI, decreasing BMD T-score and all clinical risk factors used alone or combined. The 10-year probabilities of a major osteoporosis-related fracture that corresponded to current reimbursement guidelines ranged from approximately 7.5% at the age of 50 years to 26% at the age of 80 years where a prior fragility fracture was used as an intervention threshold. For women at the threshold of osteoporosis (femoral neck T-score = -2.5 SD), the respective probabilities ranged from 7.4% to 15%. Several combinations of risk-factor profiles were identified that gave similar or higher fracture probabilities than those currently accepted for reimbursement in Belgium.
The FRAX® tool has been used to identify possible thresholds for therapeutic intervention in Belgium, based on equivalence of risk with current guidelines. The FRAX® model supports a shift from the current DXA-based intervention strategy, towards a strategy based on fracture probability of a major osteoporotic fracture that in turn may improve identification of patients at increased fracture risk. The approach will need to be supported by health economic analyses.
本研究旨在评估比利时版世界卫生组织(WHO)骨折风险评估(FRAX®)工具,以计算男性和女性的骨质疏松性骨折 10 年概率。特别目的是确定与比利时骨质疏松症管理报销政策相对应的骨折概率以及具有等效骨折概率的临床情况。
骨折概率根据比利时发表的骨折和死亡风险数据计算得出。概率考虑了年龄、性别、临床危险因素和股骨颈骨密度(BMD)。确定了与比利时目前使用的干预(报销)阈值等效的骨折概率。
骨折概率随年龄增长、BMI 降低、BMD T 评分降低以及单独或联合使用所有临床危险因素而增加。与当前报销指南相对应的主要骨质疏松性骨折 10 年概率从 50 岁时的约 7.5%到 80 岁时的 26%不等,其中脆性骨折既往用作干预阈值。对于骨质疏松症(股骨颈 T 评分=-2.5 SD)的女性,相应的概率范围从 7.4%到 15%不等。确定了几种危险因素特征组合,其骨折概率与比利时目前接受的报销概率相似或更高。
FRAX®工具已用于根据与当前指南的等效风险,确定比利时治疗干预的可能阈值。FRAX®模型支持从当前基于 DXA 的干预策略向基于主要骨质疏松性骨折概率的策略转变,这反过来可能会提高对高骨折风险患者的识别能力。该方法需要通过健康经济分析来支持。